The prevalence and predictors of resistant hypertension in high‐risk overweight and obese patients: A cross‐sectional study based on the 2017 ACC/AHA guidelines. Issue 10 (26th August 2019)

• Record Type: Journal Article
• Authors: Haddadin, Faris; Sud, Karan; Munoz Estrella, Alba; Moctezuma, Sananda; Wu, Lingling; Berookhim, Joshua; Lucas, Claire Huang; Patel, Dipal; Argulian, Edgar
• Is Part Of: Journal of clinical hypertension. Volume 21:Issue 10(2019)
• Page Start: 1507
• Page End: 1515
• Publication Date: 2019-08-26
• Subjects: obese -- overweight -- resistant hypertension; Hypertension -- Periodicals; 616.132
• DOI: 10.1111/jch.13666
• Languages: English
• ISSNs: 1524-6175

Abstract

Abstract: Obesity is significantly associated with uncontrolled blood pressure and resistant hypertension (RH). There are limited studies on the prevalence and determinants of RH in patients with higher body mass index (BMI) values. Since the hypertension guidelines changed in 2017, the prevalence of RH has become unknown and now is subject to be estimated by further studies. We conducted a cross‐sectional study in an urban Federally Qualified Health Center in New York City aiming to estimate the prevalence of RH in high‐risk overweight and obese patients based on the new hypertension definition, BP threshold ≥130/80 mm Hg, and also to describe the associated comorbid conditions in these patients. We identified 761 eligible high‐risk overweight and obese subjects with hypertension between October 2017 and October 2018. Apparent treatment‐RH was found in 13.6% among the entire study population. This represented 15.4% of those treated with BP‐lowering agents. True RH confirmed with out‐of‐office elevated BP was found in 6.7% of the study population and 7.4% among patients treated with BP‐lowering agents. Prevalence was higher with higher BMI values. Those with true RH were more likely to be black, to have diabetes mellitus requiring insulin, chronic kidney disease stage 3 or above and diastolic heart failure. In conclusion, obesity is significantly associated with RH and other significant metabolic comorbid conditions.